Luye Pharma Group Ltd.
🇨🇳China
Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 850
- Registration Number
- NCT04859569
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
Phase 3
Completed
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: LY03005 extended-release tabletDrug: Placebo
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 558
- Registration Number
- NCT04853407
- Locations
- 🇨🇳
The Sixth Hospital of Peking University, Beijing, China
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04638491
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, Jilin, China
A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04630860
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, China
A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04629404
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, China
A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04627155
to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers
Phase 1
- Conditions
- Parkinson's Disease
- Interventions
- Drug: LY03009 F4Drug: LY03009 F2Drug: LY03009 F1Drug: LY03009 F3
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04593511
- Locations
- 🇦🇺
CMAX clinical Research Pty Ltd, Adelaide, South Australia, Australia
Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04572685
- Locations
- 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 416
- Registration Number
- NCT04572698
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
Phase 3
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: LY03003(Rotigotine,extended-release microspheres)Drug: Placebo,extended-release microspheres
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 294
- Registration Number
- NCT04571164
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath